Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 139

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 139
---
 others related to the election of our board of directors or the appointment of members of our senior management.
There are furthermore no family relationships among any directors or members of our senior management.

B. Compensation

Aggregate and Individual Compensation of Officers and Directors

The aggregate compensation, including non-cash share-based compensation
(consisting of expenses related to option grants), accrued by us in respect of the year ended December 31, 2024 to all persons who served
as directors and/or executive officers during that year, was approximately $3.8 million. That amount includes approximately $0.1 million
of gross compensation set aside or accrued for executive officers for purposes of pension, severance, retirement, car, phone or similar
benefits or expenses, but does not include business travel, relocation, professional and business association dues and expenses reimbursed
to executive officers, and other expenses commonly reimbursed by companies in Israel. These amounts include the partial-year compensation
paid to seven executive officers, who served in their positions over the course of 2024 and whose employment as executive officers either
was terminated or has commenced during 2024.

During 2024, we granted our executive officers and directors an
aggregate amount of 152,600 options. Of the options granted, 9,000 were granted with an exercise price of NIS 26.6 ($7.29), 3,600 were
granted with an exercise price of $6.6 per share, and 140,000 were granted with an exercise price of NIS 8.62 ($2.36) per share. The options
detailed above expire within ten years from the date of grant. During 2024, two executive officers, who serve as chief executive officers
in two of our subsidiaries, were granted options to purchase equity of such subsidiaries, which are not detailed above. The number of
options above, and their respective exercise prices, are presented on an as-adjusted basis, after giving effect to the Reverse Split.

The following table presents information regarding compensation
accrued in our financial statements for the year ended December 31, 2024 for our five most highly compensated executive officers, as required
under Israeli Securities Law 5728-1968 and the regulations promulgated thereunder.

                                                  (in thousands, US$)(1)                            
  Name and Position                          Salary and related benefits                            
  Ofer Haviv                                                         374      49        1      424  
  Amit Noam